[Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
Three new antigens reacting with monoclonal antibodies; CA 19/9, CA 125 and DuPan 2, were evaluated for their clinical significance in the diagnosis of pancreatic carcinoma. CA 19/9 is confirmed to be the best marker in its specificity (97%) and sensitivity (85%). Even in patients with small carcinoma, 5 of 6 T 1 cases showed positive CA 19/9 values. Transient elevations were noted in obstructive jaundice either with malignant tumors or benign but chronic inflammatory process. CA 125 is elevated in 85% of patients with pancreatic carcinoma. It is considered to be a marker indicating serosal, namely peritoneal or pleural, invasion not only in malignant but also in benign diseases. A sandwich solid phase radioimmunometric assay for DuPan 2 was established and elevated antigenic levels were detected in 80% of patients with advanced pancreatic carcinoma.
D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000276:immunology; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000276:immunology; D010195:Pancreatitis / Q000175:diagnosis / Q000276:immunology; D011863:Radioimmunoassay
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; C042317:DU-PAN-2 antigen, human